ClinicalTrials.gg
Active, not recruitingNCT06100887FOXUpdated Nov 6, 2025

Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy

A Phase 2 interventional study of Sevasemten Dose 1 and Sevasemten Dose 2 in Duchenne Muscular Dystrophy, sponsored by Edgewise Therapeutics, Inc.. Active, not recruiting at 7 sites in United States. Open to male participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-11-06.

Sponsored by Edgewise Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
43
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 232 studies in Muscular Dystrophy, Duchenne with a site in United States — 34 open to participants now, 60 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · United States.

Enrollment
66th of 171
43 · median 25
Started
2024
with 14 others
Phase 2
57 of 232
4 open now
Primary completion
2027-03
later than 18 of 59 live
Registered
199th of 232
by date
Lead sponsor
6 of 232
Edgewise Therapeutics, Inc.

Among the 232 studies in Muscular Dystrophy, Duchenne with a site in United States, this one is the 66th largest by enrollment of the 171 interventional ones that give a count, is one of 15 that started in 2024, is one of 57 in phase 2, reaches primary completion later than 18 of the 59 other live ones, and was the 199th registered.

Muscular Dystrophy, Duchenne

481 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 106 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

34 of the 232 studies in Muscular Dystrophy, Duchenne with a site in United States are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 65 Muscular Dystrophy, Duchenne studies recruiting now, 30 (46%) set no upper age limit and 33 (51%) stop at 75 or younger; 58 take children under 18; 11 take healthy volunteers.

This study: 6 Years to 17 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 232 studies in Muscular Dystrophy, Duchenne with a site in United States, or all of them as a file.
02

Study summary

The FOX study is a 2-part, multicenter, Phase 2 study of safety, pharmacokinetics, and biomarkers in children and adolescents with Duchenne muscular dystrophy previously treated with gene therapy including a randomized, double-blind, placebo-controlled Part A, followed by an open-label part B.

Read the detailed description

FOX is a 2-part, multi-center, Phase 2 study to evaluate the effect of sevasemten (EDG-5506) on safety, pharmacokinetics and biomarkers of muscle damage in approximately 48 children and adolescents with Duchenne muscular dystrophy treated with oral, once-daily sevasemten. This study will have up to a 4-week Screening period, a 12-week randomized double-blind, placebo-controlled treatment period (Part A), followed by up to a 144-week open-label extension period (Part B).

Approximately forty-eight (48) participants aged 6 to 17, inclusive, will be randomized to sevasemten or placebo in a 2:1 ratio. Three dose cohorts (Cohort 1, Cohort 2 and Cohort 3) of approximately 12 participants each will be enrolled. Approximately 12 additional participants may be added to 1 of these cohorts.

After review of emerging data, the protocol was amended so all dose cohorts receive the same dose in Part B.

03

Conditions studied

  • Duchenne Muscular Dystrophy

Keywords

  • Duchenne Muscular Dystrophy
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Aged 6 to 17 with a documented mutation on the DMD gene and phenotype consistent with DMD.
  • Prior receipt of an AAV-based gene therapy (≥ 2 years after documented receipt of gene therapy administration or ≥ 3 years after randomization in a randomized study).
  • Able to complete stand from supine in ≤ 8 seconds at the Screening visit and able to perform the 4-stair climb in \< 10 seconds at the Screening visit.
  • Body weight ≥ 15 kg at the Screening visit.
  • Treatment with a stable dose of for a minimum of 6 months prior to the Baseline visit.

Key Exclusion Criteria:

  • Medical history or physical exam/laboratory result that, in the opinion of the investigator, would render the participant unsuitable for the study. This includes venous access that would be too difficult to facilitate repeated blood sampling.
  • Screening visit cardiac echocardiography showing (LVEF) \< 40%.
  • Receipt of an drug (other than the AAV-based gene therapy per Inclusion criteria) within 30 days or 5 half-lives (whichever is longer) of the Screening visit in the present study.
  • Receipt of an exon-skipping therapy within 6 months prior to the Screening visit.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Drug: Sevasemten Drug: Placebo

    Drug: Sevasemten Dose 1 · Drug: Placebo

  • Experimental
    Cohort 2

    Drug: Sevasemten Drug: Placebo

    Drug: Sevasemten Dose 2 · Drug: Placebo

  • Experimental
    Cohort 3

    Drug: Sevasemten Drug: Placebo

    Drug: Sevasemten Dose 3 · Drug: Placebo

Interventions

  • DrugSevasemten Dose 1

    Sevasemten is administered orally once per day

  • DrugSevasemten Dose 2

    Sevasemten is administered orally once per day

  • DrugSevasemten Dose 3

    Sevasemten is administered orally once per day

  • DrugPlacebo

    Placebo is administered orally once per day

06

What researchers measure

Primary outcomes

  1. Number of adverse events during treatment with sevasemten or placebo

    All participants

    Time frame: 36 months

  2. Severity of adverse events during treatment with sevasemten or placebo

    All participants

    Time frame: 36 months

Secondary outcomes

  1. Incidence of laboratory test-related treatment emergent adverse events

    All participants

    Time frame: 36 months

  2. Pharmacokinetics as measured by steady state plasma concentration

    All participants

    Time frame: 36 months

  3. Change from Baseline in serum creatine kinase

    All participants

    Time frame: 12 weeks

  4. Change from Baseline in fast skeletal muscle troponin I

    All participants

    Time frame: 12 weeks

07

Study locations

7 sites
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Mar 2027, 36 months after the start.

Of 40 industry-sponsored phase 2 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 42. This study's planned 36 months is above that.

Counting every sponsor, half of 47 studies reached it within 31 months; a quarter within 20 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2023
First posted
Oct 25, 2023
StartActual
Mar 22, 2024
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Nov 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06100887
Lead sponsor
Edgewise Therapeutics, Inc.
Responsible party
Sponsor
First posted
Oct 25, 2023
Start date
Mar 22, 2024
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Nov 6, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion